Aug 13, 2026 02:45AM
Aug 12, 2026 06:05AM
Aug 12, 2026 06:00AM
Aug 12, 2026 06:00AM
Aug 6, 2026 04:16PM
Aug 6, 2026 08:04AM
Aug 6, 2026 08:00AM Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Jul 30, 2026 04:01PM
Jul 30, 2026 04:01PM
Jul 14, 2026 04:05PM
Jul 14, 2026 04:05PM
May 7, 2026 04:01PM
Mar 30, 2026 04:01PM
Feb 17, 2026 08:00AM Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Jan 8, 2026 08:00AM
Dec 1, 2025 04:17PM
Nov 10, 2025 04:05PM
Aug 14, 2025 04:05PM
Aug 7, 2025 04:31PM Annexon selected for EMA pilot program for dry AMD treatment
Aug 7, 2025 04:30PM
Jul 24, 2025 07:00AM
Jul 24, 2025 07:00AM
Jun 18, 2025 04:05PM
May 19, 2025 04:07PM
May 19, 2025 04:05PM
May 12, 2025 08:00AM Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 9, 2025 05:00PM
May 7, 2025 08:00AM
Apr 9, 2025 07:00AM
Apr 8, 2025 04:05PM
Apr 3, 2025 06:18PM
Mar 3, 2025 08:00AM
Feb 13, 2025 08:30AM Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
Dec 17, 2024 06:53AM
Dec 16, 2024 07:31AM
Dec 16, 2024 07:30AM
Dec 5, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 21, 2024 08:00PM
Oct 15, 2024 08:02AM Annexon (ANNX) to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Oct 15, 2024 08:00AM
Sep 9, 2024 08:00AM
Aug 13, 2024 09:28AM
Aug 12, 2024 08:00AM
Aug 5, 2024 08:00AM
Jul 11, 2024 06:09PM
Jun 25, 2024 05:00PM Annexon (ANNX) Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome
Jun 25, 2024 05:00PM

329,908 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All